The establishment of an ARRGRS consisting of 10 biomarkers (S100A4, ASCC3,EPB41L2,NET1,TEX30,CSPG4, MPO,PDE4A, RASAL3,SHANK1) based on differential genes associated with cytarabine resistance was used to categorize AML patients, which helped to assess the overall survival of these patients and response to cytarabine-based therapy. This evidence concerns the gene PDE4A and acute myeloid leukemia.